



***MitoAction and Care3 Announce Global Innovation Partnership
Focused on Mitochondrial Disease***

For Immediate Release

June 12, 2018

(Boston, MA) – MitoAction (www.mitoaction.org), a leading patient advocacy organization within the mitochondrial disease community and Care3™ (www.care3.co), the world's first team collaboration platform for healthcare delivered in the home and community, announce an innovation global partnership focused on advancing the knowledge of and care delivery for mitochondrial disease. This partnership aims to provide a unique platform to help families manage the complexities of day-to-day care, as well as facilitate enhanced communication with their personal and clinical care teams. Through development and deployment of this joint venture of the award-winning Care3 care collaboration platform, critical details will be captured to help researchers and clinicians learn more about this rare disease, to aid in the development of therapies and ultimately a cure for mitochondrial disease.

“The platform that has resulted from this partnership will not only help families to manage their daily journey with mitochondrial disease, but will also improve communication with their care team and allow clinicians and researchers to gain a better understanding of the disease.” said Kira Mann, CEO of MitoAction. “We believe this platform is the first step in transforming the management and delivery of care, not only for those affected by mitochondrial disease, but the entire rare disease community. We are incredibly proud of our new partnership with Care3 and believe with this type of collaborative innovation allows us to push the envelope on what is possible in utilizing technology with rare disease care. “

Care3 currently serves the senior care community through partnerships with Programs of All-Inclusive Care for the Elderly (PACE) for collaboration on care in the home and at PACE centers.

“In addition to senior care, Care3 can help the mitochondrial disease community better understand the challenges faced by families affected by mitochondrial disease and the correlations that exist between diagnosis, symptoms, treatment plan execution and quality of life,” adds David S. Williams, Co-Founder & CEO of Care3. “It’s our mission to bring healthcare equality to everyone and mitochondrial disease hasn’t received the innovation attention it deserves.”



MitoAction and Care3 plan to launch the joint platform in Summer of 2018 as the first phase in the multi-phase partnership. For more information, visit www.mitoaction.org/care3 and www.care3.co/mitoaction.

About MitoAction

MitoAction is a Boston based nonprofit whose mission is to improve the quality of life for children, adults, and families living with mitochondrial disease through support, education, outreach, advocacy, and clinical research initiatives. Since its founding in 2005, MitoAction has served families from across the U.S. and the globe, working tirelessly to offer comprehensive, up-to-date, expert resources, information, and support at no cost to any patient, family, clinician, educator, or member of the community. Learn more at www.mitoaction.org.

About Care3™

Care3™ is the world's first team collaboration platform for healthcare delivered in the home and community. The HIPAA compliant Care3 platform helps collaborative care programs (e.g. PACE) operate more effectively by driving visibility and accountability for care delivered outside of health facilities. This unprecedented insight enables care teams to intervene to prevent costly outcomes such as emergency visits and hospitalizations. Learn more at www.care3.co.

Press Contact

Kira Mann, CEO, MitoAction

E-mail: kira@mitoaction.org

www.mitoaction.org/care3